Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Towards a Precise NMR Quantification of Acute Phase Inflammation Proteins from Human Serum
Ist Teil von
Angewandte Chemie, 2023-08, Vol.135 (35), p.n/a
Ort / Verlag
Weinheim: Wiley Subscription Services, Inc
Erscheinungsjahr
2023
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
Nuclear Magnetic Resonance (NMR) spectra of human serum and plasma show, besides metabolites and lipoproteins, two characteristic signals termed GlycA and B arising from the acetyl groups of glycoprotein glycans from acute phase proteins, which constitute good markers for inflammatory processes. Here, we report a comprehensive assignment of glycoprotein glycan NMR signals observed in human serum, showing that GlycA and GlycB signals originate from Neu5Ac and GlcNAc moieties from N‐glycans, respectively. Diffusion‐edited NMR experiments demonstrate that signal components can be associated with specific acute phase proteins. Conventionally determined concentrations of acute phase glycoproteins correlate well with distinct features in NMR spectra (R2 up to 0.9422, p‐value <0.001), allowing the simultaneous quantification of several acute phase inflammation proteins. Overall, a proteo‐metabolomics NMR signature of significant diagnostic potential is obtained within 10–20 min acquisition time. This is exemplified in serum samples from COVID‐19 and cardiogenic shock patients showing significant changes in several acute phase proteins compared to healthy controls.
1D Nuclear Magnetic Resonance (NMR) spectra of human serum show two characteristic signals originating from acute phase glycoprotein glycans, termed GlycA and B. We have unambiguously assigned them to Neu5Ac and GlcNAc moieties from N‐glycans, respectively. They can be used for the simultaneous quantification of several acute phase inflammation proteins in 10–20 min. The method is illustrated with serum samples from COVID‐19 patients.